Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

Inclusion Criteria: * Clinically definite multiple sclerosis defined by McDonald Criteria (8) with a score of 0 to 5.5 on the Expanded Disability Status Scale (EDSS)(9). Inclusion will also be determined by PI if clinically indicated. Relapsing remitting form of MS. * Between 18-65 years of age (This age range is selected so as to capture the vast majority of patients who are seen in the clinics with a confirmed diagnosed of MS. This age range also allows for exclusion of co-morbid conditions that may be associated with aging as well as pediatric cases where their disease characteristics have been shown to be different). * Ability to understand and sign the IRB-approved informed consent form prior to the performance of any study-specific procedures and is willing to comply with the required scheduling and assessments of the protocol. * Women of childbearing potential must have a negative urine pregnancy test at the Screening Visit and must be willing to practice a reliable birth-control method. * Patient must be willing to discontinue and remain free from concomitant immunosuppressive or additional immunomodulatory treatment (including IFNβ1a, 1b, natalizumab and GA) for the duration of the study. * Willing to answer a series of questions about disease, ancestry, residence history, socioeconomic status and ethnic background. * Willing to donate 50cc of blood for genetic admixture and immunological testing on three occasions (O months, 6 months, 12 months). * Willing to undergo MRI as standard of care at a 1.5 Tesla magnet strength at least. Exclusion Criteria: * Inability to understand nature of the study. * Lack of a definite diagnosis of Multiple Sclerosis such as clinical isolated syndrome will be excluded. * NMO Antibody positive. * Primary progressive or secondary progressive MS. * Inability to undergo an MRI study or receive contrast agent and GFR\<30. * Considered by the Investigator to be immunocompromised, based on medical history, physical examination, or laboratory testing or due to prior immunosuppressive treatment. * Lack of Varicella immunity. * History of, or available abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric (including major depression), renal, and/or other major disease. * History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible). * Known history of human immunodeficiency virus infection, hematological malignancy, or organ transplantation, history of severe allergic or anaphylactic reactions or known drug hypersensitivity. * Prior treatment history with the interferons, glatiramer acetate or natalizumab will be acceptable after drug clearance of 1 month. 1 month has been selected due to clinical experience of possible disease breakthrough if longer period is performed.